SRZN (Surrozen) Buyback Yield % : -19.27 (As of Apr. 16, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Surrozen Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Surrozen's current buyback yield was -19.27%.

Surrozen Buyback Yield % Historical Data

The historical data trend for Surrozen's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Buyback Yield % Chart

Surrozen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

-55.05

14.89

0.02

-34.40

Surrozen Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial													0.02	-	-	-	-34.40

Competitive Comparison of Surrozen's Buyback Yield %

For the Biotechnology subindustry, Surrozen's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surrozen's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Surrozen's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Surrozen Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Surrozen's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	16.043)	/	46.6375
	=	-34.40%

Surrozen's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	16.043)		/	46.6375
	=	-34.40%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Surrozen Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Surrozen's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Surrozen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.surrozen.com

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Executives

Charles O Williams	officer: Chief Financial Officer	C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Tim Kutzkey	director, 10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Anna Berkenblit	director	830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md	director, 10 percent owner	1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai	director	2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh	officer: Chief Scientific Officer	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory	other: Former VP Business Development	C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove	officer: Chief Medical Officer	1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Mace Rothenberg	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel	other: Former Director	4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse	director	630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158